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A Pathway to Follow-On Biologics
by JEANNE YANG*
I. Introduction
Over the past several decades, advances in biotechnology and
medicine have created an influx of biologics. Biologics (e.g., insulin,
human growth hormone) are complex, protein molecules that are
used to treat a variety of ailments. In contrast to chemical drugs (e.g.,
aspirin, ibuprofen), which are simple, small-molecule compounds
easily created by chemists and produced in pill form, biologics are
large, complex molecules produced by bioengineered bacteria and
other organisms. Biologic products have shown great promise as
effective treatments for cancer, autoimmune diseases, and other
serious afflictions.' Many drug manufacturers, enticed by the promise
of patent protection and strong market rates, have entered the field,
developing innovative, therapeutic biologics.2
Unfortunately, two major factors limit the reach of biologic
development: cost and safety. First, the cost of treatment with
biologics is expensive and can reach hundreds of thousands of dollars
per year,' a result of the high cost of development and clinical testing.
This cost makes it difficult for many patients to obtain necessary
treatment for specific ailments. The benefits of biologics are lost if
patients cannot afford to pay for them. Second, safety issues arise
* J.D. Candidate, University of California, Hastings College of the Law, 2011; B.S.
Biochemistry, University of Maryland, College Park, 2007. The author would like to
express her appreciation to Professor Robin Feldman of the Law and Bioscience Program
at U.C. Hastings College of the Law and Josh Kim, Ph.D., of Jones Day for their insight
and invaluable advisement on this Paper.
1. N. Lee Rucker, Biologics in Perspective: Expanded Clinical Options Amid Greater
Cost Scrutiny Fact Sheet, AARP Public Policy Inst., June 11, 2007,
http://www.aarp.org/healthl/drugs-supplements/info-2007/fsl 36_biologics.html.
2. Fed. Trade Comm'n, Emerging Health Care Issues: Follow-on Biologic Drug
Competition 3 (June 2009), available at http://www.ftc.gov/os/2009/06/PO83901
biologicsreport.pdf
3. Ingrid Kaldre, The Future of Generic Biologics: Should the United States 'Follow-
On' the European Pathway?, 9 DUKE L. & TECH. REV. 1, 4 (2008).
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from the fact that biologics are larger and more complex than small-
molecule drugs, making production, quality control, and quality
assurance more difficult. Even small changes in a biologic's
manufacture could adversely change its chemical properties and the
way it affects individuals.
Competition from generic versions of brand name biologics,
known as "follow-on biologics," would address the cost issue by
supplying patients with cheaper alternatives as well as providing
incentive for generic biologic manufacturers to continue research and
development. However, there is currently no legislative framework
to address the approval of generic biologics. Under the Public Health
Safety Act ("PHSA"), generic biologics must endure the same
approval process as the original, reference biologics.! The current
process for follow-on biologics requires an applicant to duplicate the
same type of clinical test cycles that the original, brand name biologic
had to go through prior to its approval.' Conducting clinical testing
for generic biologics is an inefficient use of scarce resources and
deters generic biologics competitors from entering the market. An
approval process that balances safety and efficacy concerns with the
cost and resources of generic biologics is necessary.
Addressing the issues facing biologics becomes even more
important when considering the high costs of biologics and a strained
healthcare system. Healthcare reform will ultimately demand
cheaper, affordable biologics. There are already several bills pending
in Congress addressing this issue. It is only a matter of time before an
abbreviated approval pathway is approved. The need for an approval
process for follow-on biologics is heightened by the large number of
biologics that will go off-patent in the next several years. It is
4. Brand-name biologics are often called "pioneer" or "branded" biologics, and
these terms are used interchangeably. When used in context with generic biologics,
pioneer biologics are also referred to as "reference" biologics because they provide the
reference from which the generic biologics are developed. The Federal administrative
agencies in the U.S. refer to generic biologics as "follow-on biologics," while the European
Union uses the term "biosimilars." Both terms refer to the same thing, but this Paper will
use the term "follow-on biologics" for generic biologics in the United States and
"biosimilars" when addressing generic biologics in the E.U.
5. AARP Public Policy Institute, supra note 1, at 3.
6. Gregory N. Mandel, Note, The Generic Biologics Debate: Industry's Unintended
Admission that Biotech Patents Fail Enablement, 11 VA. J.L. & TECH. 1, 23 (2006).
7. See id. at 4-5. Sixteen of 27 of the top-selling biologic products comprising
approximately 87 percent, or $112 billion worth, of today's total global value of the
biologics industry were approved before 2000 and are now set to expire by the year 2014.
Id.
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estimated that $10 billion worth of biologic drugs will go off-patent by
2010, with an additional $10 billion going off-patent by 2015.'
The process for generic small-molecule drug approval is greatly
aided by the fact that a generic drug manufacturer can easily establish
that its product and the original are the same.' There is currently no
comparable approval pathway for generic biologics. The absence of
an approval pathway means that generic biologic manufacturers have
little incentive to enter a market in which there is a large barrier to
entry. Generic manufactures would have to spend a large amount of
money recreating clinical research in order to demonstrate that their
generic has the same safety and efficacy as the original. Not only is
this not cost-effective, but it also gives brand name manufacturers a
de facto extension on their patents. United States patent law protects
inventors by giving a patent owner the right to prevent others from
using the patent in any manner during its lifetime.") A de facto
extension of a patent occurs when competitors are unable to develop
products until it has expired. This gives the original patent an extra
period of protection while competing products are researched,
developed, and produced. In the case of generic biologics, generic
manufacturers are restricted from conducting comparative clinical
trials during the patent life of a pioneer biologic, forcing them to wait
for the patent expiration before starting testing." To avoid this,
legislation such as the Hatch-Waxman Act has proposed abbreviated
approval pathways, permitting companies to use data in ways that
would normally be considered patent infringement. This use of data
would allow generic drugs to enter the marketplace immediately after
the expiration of the original product's patent.
8. Rachel Chu & Meir Pugatch, Biogenerics or Biosimilars? Discussing the Present,
Considering the Future, Stockholm Network (2009), http://www.stockholm-network.org/
downloads/publications/BiosimilarsFINAL.pdf.
9. Alan J. Morrison, Biosimilars in the United States: A Brief Look at Where We Are
and the Road Ahead, 26 BIOTECHNOLOGY L. R. 463, 465 (2007).
10. All patents with a filing date after June 8, 1985, have a patent period of 20 years
from the date of filing. Patents filed in the United States prior to that date have a patent
period of 17 years from the patent's date of issue. 35 U.S.C. § 154 (2002).
11. Under the Hatch-Waxman Act, generic drug makers can use brand name drugs in
clinical trials that would otherwise be considered patent infringement provided that the
use is related to obtaining FDA approval. To preserve the incentive for brand name
companies to continue their research and to compensate for time lost due to waiting for
FDA approval, the Act allows for de facto extensions under certain circumstances. Fed.
Trade Comm'n, GENERIC DRUG ENTRY PRIOR TO PATENT EXPIRATION: AN FTC
STUDY 4 (2002), available at http://www.ftc.gov/os/2002/07/genericdrugstudy.pdf.
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This paper discusses issues that the biologics industry faces
today, analyzes bills for abbreviated approval pathways for follow-on
biologics currently pending approval in Congress, and proposes
several adjustments to those bills. First, this Paper examines why
follow-on biologics were not included within the Hatch-Waxman Act.
It then discusses the implications of the Hatch-Waxman framework
on follow-on biologics and finds that it cannot apply to biosimilars
without significant changes to ensure their safety, purity, and potency
to match those of the original, reference biologic. In light of the
current economy and the high cost of development, manufacturing,
and clinical testing, an abbreviated approval pathway for follow-on
biologics is the most likely option. Lastly, this paper proposes that a
pathway for abbreviated approval should adopt a different standard
so as to be more structured than the current proposals before
Congress. Any abbreviated approval pathway should require a one
year statutory-mandated clinical trial period to ensure the safety of
the product. Follow-on biologics should also be required to be
"substitutable," requiring a "sameness" between proposed biologics
and their respective brand name biologic, as opposed to merely being
"similar." Furthermore, I suggest that, while the bills await approval
before Congress, the FDA should develop guidelines for approving
the generic versions of well-characterized biologics, such as insulin,
for which safety is less of a concern because they already have a
substantial history of safe use.
II. What are Biologics?
According to the PHSA, biologics are a class of biological
products derived from living organisms that are used to diagnose,
treat, or prevent various medical conditions.12 Biologics, which are
also known as biopharmaceuticals, biologic drugs, or protein drugs,"
are mostly protein products. They include vaccines, blood and blood
components, gene therapy, tissues, and recombinant therapeutic
proteins.14 Originally, biologics were created from purified extracts of
12. 42 U.S.C. § 262(i) (2009); Dept. of Homeland Security Revocation of Notice, 7
C.F.R. § 205.2 (2009).
13. The Public Health Service Act ("PHSA") uses the term "biologics" when
referring to biological products. However biologics go by many other names. Terms such
as "biopharmaceuticals," "biologic drugs," and "protein product" are used
interchangeably in the literature addressing these issues.
14. Food and Drug Administration, About FDA: What Are "Biologics" Questions and
Answers, http://www.fda.gov/AboutFDA/CentersOffices/CBER/ucml33077.htm (last
visited October 30, 2009) (hereinafter FDA).
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animal blood and tissue, but advances in biotechnology have pushed
their development toward recombinant DNA technology. This
technology consists, essentially, of reprogramming cell lines to mass
produce specific biological products.' Today the majority of biologics
is created by engineering bacterial and yeast cell lines to produce
desired proteins." Conventional small-molecule drugs, on the other
hand, are derived from chemical compounds and "can be completely
characterized on the basis of their chemical structures.""
A. Biologics as Differentiated from Chemical Drugs
Biologics attain a level of complexity that far outreaches simple
molecules and other chemical drugs both structurally and
functionally." According to the FDA, most conventional chemical
drugs, such as the ones people recognize in their local pharmacies
(e.g., Advil@, Tylenol@, and Lipitor@), are created by combining a
series of well-defined chemicals in a highly predictable manner to
create a product that, despite being created by very different
processes, results in an identical final product." Small-molecule,
chemical drugs are considered to be chemically, and not biologically,
synthesized and usually involve a single, chemical entity. In
contrast, proteins comprise the majority of biologic drugs and
illustrate the complexity of biologics.2' Protein products are often too
large and complex to be created chemically, which is why scientists
insert specific DNA sequences into cells, essentially "programming"
bacteria and other living organisms to produce the target biologic.22
Structurally, proteins vary widely in size, with some proteins
having as few as three amino acids while others have as many as
2,300.23 Proteins are often much larger than chemical drugs. For
15. Robert N. Sahr, The Biologics Price Competition and Innovation Act: Innovation
Must Come Before Price Competition, 2009 B.C. INTELL. PROP. & TECH. F. 070201, July
19, 2009, at 6.
16. Id. at 6-7.
17. Scott Gottlieb, Biosimilars: Policy, Clinical, and Regulatory Considerations, 65
AM. J. HEALTH-SYS. PHARMACY, no. 14, at S4 (Supp. 6 July 15, 2008).
18. Morrison, supra note 9, at 465.
19. Why is Patient Safety A Concern in the Biosimilars Debate?, BIOTECHNOLOGY
INDUSTRY ORG., http://www.bio.org/healthcare/followonbkg/PatientSafety.asp (last
visited December 15, 2009).
20. FDA, supra note 14.
21. Sahr, supra note 15, at 7.
22. Id. at 10.
23. Sahr, supra note 15, at 8.
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example, aspirin has a molecular weight of 180 Da, while the biologic
interferon-13 (used to treat and control multiple sclerosis) has a
molecular weight of 19,000 Da.24 Furthermore, two protein products
with identical amino acid sequences can still lack comparable
functionality due to differences in their folding patterns, post-
translational modifications, and aggregations of subunits.2' The
consequences of subtle differences between proteins with identical
amino acid sequences can be significantly dangerous. These dangers
were demonstrated by the observed side-effects of Epogen and
Eprex, two genetically engineered forms of the human hormone
erythropoietin used to treat anemia in patients with chronic renal
failure.2' The specifics of the Epogen and Eprex example are
discussed below.
Other differences between biologic drugs and chemical drugs
include delivery method, mode of action, and manufacturing methods
and costs. While most chemical drugs are administered orally via pill
form, biologics are often unstable and easily degrade in the digestive
system before reaching the blood stream. Therefore, many biologics
must be injected or inhaled in order maximize efficacy within the
human body.7 Biologics can also be "heat sensitive and susceptible to
microbial contamination" and must be cared for accordingly, by
maintaining their stable storage environments and developing
administration methods that preserve their efficacy in the human
body.28 Additionally, a biologic can affect up to 100 different
physiological processes in the body (as opposed to a chemical drug's
mere handful of reactions within the body), making it very difficult
for researchers to predict physiological responses to specific
biologics. 29 Lastly, biologics are much more expensive to develop and
24. Micha Nowicki, Basic Facts about Biosimilars, 30 KIDNEY & BLOOD PRESSURE.
RES. 267, 268 (2007), available at http://content.karger.com/produktedb/ produkte.asp?typ
=fulltext&file=000105133.
25. See id. Amino acids are the building blocks of proteins. A protein is made of one
or more strands of amino acids, also known as polypeptides, that has folded in on itself
based on the hydrophobic and hydrophilic interactions of each amino acid's specific side
chains. See J. Stein Carter, Amino Acids and Proteins, U. CINCINNATI, http://biology.clc.
uc.edu/courses/bioIO4/protein.htm (last modified Nov. 2, 2004). Depending on the pH,
temperature, and other environmental factors, the polypeptides that make up a protein
may react and correspondingly fold into other configurations or, in some instances,
denature and completely lose its original configuration.
26. EPOGEN, http://www.epogen.com (last visited November 5, 2009).
27. Kaldre, supra note 3, at 10.
28. FDA, supra note 14.
29. Nowicki, supra note 24, at 267.
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manufacture than chemical drugs.3" Due to the complex and
unpredictable nature of biologics, it is crucial that the biologics
endure stringent safety review and testing. While chemical drugs only
require 40-50 clinical tests, the average biologic requires 250 clinical
tests or more.' The aforementioned differences between biologics
and chemical drugs are why the costs of biologics have risen so
sharply over the past couple of decades.
B. What are Follow-On Biologics?
When conventional, small-molecule drugs expire, generic
versions of the drugs jump onto the scene, ready to grab a share of
the pharmaceutical market. When patent protections and regulatory
protections of pioneer biologics expire, companies create follow-on
biologics. These are attempts to copy the original biologics and are,
in essence, generic versions of the original.32 However, while generic
chemical drugs can be identical to the original, brand name drug, it is
virtually impossible to create identical follow-on biologics. Chemical
drugs are easy to reproduce because their structures are precisely
defined.3  On the other hand, follow-on biologics are copies of
existing biologics made with different cell lines or different
manufacturing and purification processes.34 Using different cell lines
and manufacturing techniques will result in a variety of differences
between follow-on biologics and pioneer biologics. These disparities
are the source of many of the substitutability issues between generic
and brand name versions of biologics.
C. Problems Currently Facing Biologics
1. Exorbitant Costs Hamper the Accessibility of Biologic Drugs and
Reduce the Incentive for Follow-On Biologics Manufacturers
The high cost of the research and development necessary to
create biologics has driven the cost of receiving these drug therapies
to astronomical heights. For example, treatment of breast cancer
with Herceptin can cost $48,000 per year, and treatment of
rheumatoid arthritis with Remicade can reach approximately $20,000
30. Kaldre, supra note 3, at 15.
31. Id. at 14.
32. Nowicki, supra note 24, at 268.
33. Id.
34. Id.
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per year." In contrast, the most expensive small-molecule, chemical
drug treatment currently on the market costs approximately $300 per
patient per year." Biologics are among the most expensive items in
the U.S. healthcare budget. In 2007, Americans spent $40.3 billion
on biologics alone.
Part of the reason behind the rising costs of biologics is that
advances in biotechnology have invariably been accompanied by
price increases. For example, Fred Banting and Charles Best, the
discoverers of insulin, sold the patent for one dollar in an effort to
keep it cheap and accessible. 9 The original form of insulin developed
by Banting and Best was extracted from pig and cow pancreases and
did not last long in the human body. It required significant
improvements to lengthen its effectiveness.4  Yet even such
improvements had low accompanying price increases, selling for only
$2.99 a bottle in 1975.4' However, in 1978, Genentech created the first
biologic drug: insulin created by genetically engineered bacteria,
which produced insulin biologically instead of chemically. 42 By 1996,
the FDA approved the first insulin analogs, which are similar to
human insulin but have been genetically manipulated to be slower- or
faster-acting.43 When these improvements hit the market, the price
for insulin skyrocketed.44  The cost of insulin to state Medicaid
programs in 2005 was $500 million.4 At the time of this writing,
popular, fast acting versions of insulin like Humalog and Novolog
cost upwards of $60 per bottle.46 Insulin is only one example of a
35. Kaldre, supra note 3, at 14.
36. Zach Patton, Complex Rx, GOVERNING MAG., Oct. 2007, at 58.
37. Megan Thisse, Working the Bugs Out of Biologics: A Look at the Access to Life-
Saving Medicines Act and Follow-On Biologics, 18 ALB. L.J. Sci. & TECH. 543, 563 (2008).
38. Id.
39. Linda von Wartburg, Why Does Insulin Cost More Than Ever? It's All in the Way
It's Made, DIABETES HEALTH, June-July 2007, at 42, available at http://www.diabetes
health.com/read/2007/05/23/5206/why-does- insulin -cost- more-than -ever-its- all -in-the-way-
its-made/.
40. Id.
41. Id.
42. Id.
43. Wartburg, supra note 39, at 43.
44. Id.
45. Thisse, supra note 37, at 563.
46. John Walsh & Ruth Roberts, Humalog and Novolog Insulins, DIABETES
NET.COM, http://www.diabetesnet.com/diabetes-treatments/insulin-humalog.php (last
visited Dec. 18, 2009).
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biologic drug that weighs heavily on the U.S. healthcare system due
to high costs.
2. Safety Issues Inherent Within Biologics
Biologics are much larger and more complex than conventional,
chemically-produced, small-molecule drugs. Even slight changes in
manufacture can greatly affect the biological composition of the
product and, subsequently, their safety and efficacy in patients.
Differences in protein configurations may occur because of the
environmental conditions in which a biologic is manufactured and will
have correspondingly different effects on individuals.
The major safety concern with biologics is immunogenicity.
Immunogenicity occurs when the body develops an allergic response
to properties intrinsic to the biologic. 48 The allergic reaction occurs
because biologics are created in cells of other organisms, and the
human body will often view them as foreign substances resulting in an
immune response and accompanying antibody production.49 In some
instances, the immune response can be so severe that patients become
allergic to even natural proteins formed by their own bodies, possibly
worsening their conditions."
Unlike processes used for creating generic chemical drugs, for
which the products can be confirmed as identical to the brand name
drug in terms of structure, safety, and efficacy despite differing
manufacturing methods, it is nearly impossible to determine whether
follow-on biologics and their pioneer biologic counterparts share the
same effectiveness and quality. Of particular concern is the fact that
the complexity of proteins opens biologics up to a varying danger of
immunogenicity. For example, two proteins with the same structure
but slightly different production methods resulted in the discovery of
Epogen and Eprex. The biologic drugs Epogen and Eprex are both
agents used to treat patients suffering from anemia (low red blood
47. BIOTECHNOLOGY INDUSTRY ORGANIZATION, Why is Patient Safety a Concern
in the Biosimilars Debate?, http://bio.org/healthcare/followonbkg/PatientSafety.asp (last
visited Nov. 5, 2009).
48. ALSTON + BIRD LLP, Health Care Advisory: Primer on Generic Biologics (Nov.
20, 2006), http://www.alston.com/ (search for "generic biologics"; then follow "Biogenerics
Primer FDA Advisory" hyperlink).
49. Gottlieb, supra note 17, at S5.
50. See Charles L. Bennett et al., Pure Red-Cell Aplasia and Epoetin Therapy, 351
NEW ENG. J. MED. 1403, 1404 (2004), available at http://content.nejm.org/cgi/
content/full/351/14/1403. (last visited November 5, 2009) (incidents of pure red-cell aplasia
due to treatment by the biologics Epogen, Eprex, and NeoRecormon, an epoetin beta
formulation.)
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cell counts) due to kidney failure or due to side effects from
treatments such as chemotherapy." Epogen and Eprex use the same
active ingredient: a man-made form of the protein erythropoietin,
called epoetin alfa. Epogen was prescribed to patients in the U.S.
while Eprex was prescribed to patients elsewhere around the world,
particularly in Europe.52 They were both produced using the same
recombinant DNA technology and had identical amino acid
sequences, but because of slight differences in the way each biologic
was manufactured the resultant drugs caused very different reactions
in their respective patients. Epogen was created in human serum
albumin while Eprex was made in glycine and polysorbate 80.54 it is
still unknown what factors were exactly responsible, but the resulting
changes in Eprex were sufficient to change its immunogenicity,
causing patients to develop pure red cell aplasia (PRCA), a syndrome
characterized by "anemia, low reticulocyte count, absence of
erythroblasts on bone marrow, resistance to epoetin therapy, and
antibodies for erythropoietin." Simply put, patients taking Eprex
began producing antibodies at much higher rates than patients taking
Epogen." The patients experienced an allergic reaction to epoetin so
severe that they also became allergic to the epoetin their bodies
produced naturally. The biologic, originally taken to improve a
patient's medical condition, effectively made them more ill. From
1988 to 1998, pure red-cell aplasia was reported in three patients who
had undergone treatment with Epogen.5 After the release of Eprex
in Europe and between January 1998 and April 2004, researchers
discovered 175 cases of epoetin-associated pure red-cell aplasia
51. Food and Drug Administration, FDA Drug Safety Communication:
Erythropoiesis-Stimulating Agents (ESAs): Procrit, Epogen and Aranesp, http://www.fda.
gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm20
0297.htm (last updated Apr. 8, 2010).
52. Charles L. Bennett et al., Long-Term Outcome of Individuals with Pure Red Cell
Aplasia and Antierythropoietin Antibodies in Patients Treated with Recombinant Epoetin:
A Follow-Up Report from the Research on Adverse Drug Events and Reports (RADAR)
Project, 106 BLOOD 3343, 3344 (2005), available at http://bloodjournal.hematologylibrary.
org/cgi/reprint/1 06/10/3343.
53. Id.
54. Id.
55. Id.
56. Sahr, supra note 15, at 14.
57. Bennett et al., supra note 50, at 1404. Red cell aplasia occurs when the body's
immune system no longer recognizes the native erythropoietin and develops an immune
response the body's own blood cells, causing the patient's anemic condition to worsen as
the patient's body begins to attack its own cells. See id.
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related to Eprex, but only 5 cases related to Epogen."' Opponents to
abbreviated approval pathways for follow-on biologics often cite this
case as proof of the dangers arising from biologics that, although
seem the same, have clearly different pharmacological effects.
The soaring prices of biologics are forcing the U.S. to spend
millions of additional dollars on healthcare. As a result, there is a
demand for generic biologics because of the exorbitant cost of buying
branded biopharmaceuticals. At the moment, generic biologic drug
manufacturers have no economic incentive to enter the field of
follow-on biologics. The possibility for a reasonable return on
investment is too low to risk investing in expensive clinical trials,
safety tests, and waiting for FDA approval. However, in light of the
number of bills pending before Congress and the looming healthcare
crisis in America, it is only a matter of time before Congress approves
an abbreviated approval pathway for follow-on biologics. The
current bills, however, are insufficient and should be adjusted to
properly accommodate for and balance the needs and concerns of all
parties involved.
III. FDA Regulatory Scheme for Brand Name and Generic
Drugs, and for Pioneer and Follow-On Biologics
The FDA regulates new drugs and biologics for approval and
licensure." Small-molecule drugs are regulated under the Food, Drug
and Cosmetics Act ("FDCA")." However, biologics are regulated
under both the Public Health Service Act ("PHSA") and the Food,
Drug and Cosmetics Act ("FDCA"). The FDCA applies to biologics
because they fall within the FDCA definition of "drugs."'
A. The Approval Process for Small-Molecule Drugs
The pre-clinical phase of developing a drug usually begins with
basic discovery and research in various academic, government, and
industry laboratories. After extensive testing on animal models, the
applicant for a drug can file an Investigational New Drug ("IND")
application.62 After the FDA evaluates the IND and grants
58. Bennett et al., supra note 50, at 1405.
59. Sahr, supra note 15, at 15.
60. Donna M. Gitter, Innovators and Imitators: An Analysis of Proposed Legislation
Implementing an Abbreviated Approval Pathway for Follow-On Biologics in the United
States, 35 FLA. ST. U. L. REV. 555, 563 (2008).
61. Id. at 563-64.
62. Id. at 565.
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permission for the applicant to conduct clinical studies on humans,
the clinical phase of testing begins.
There are three phases of clinical trials: Phase I clinical trials
involve a small group (twenty to one hundred) of healthy volunteers
to determine whether the drug is safe and effective; Phase II clinical
trials then test the drug on a larger pool of patients (several hundred)
with the specific intention of confirming that the compound has the
intended effect, at which point the drug ultimately moves on to Phase
III. Phase III, which is "the most costly stage of drug development,"
involves several thousand patients and evaluates the safety and
effectiveness of the drug. 64 At this point, approximately 64% of the
drugs in Phase III clinical testing are submitted as New Drug
Applications (NDAs) and new Biologic License Applications (BLAs)
to the FDA.'" Biologic License Applications will be discussed further
below. Until this point, the developmental and research costs of
biologics and small-molecule chemical drugs are comparable. The
average cost of bringing a small-molecule drug to market varies from
$800 million to $1.7 billion while the average cost for a biologic drug
is $1.2 billion. Once the FDA approves the new product, the drug
name and related patent information is published in the Approved
Drug Products with Therapeutic Equivalence Evaluations (the
"Orange Book").6
B. The Hatch-Waxman Act: An Accelerated Approval Pathway for
Generic Small-Molecule Drugs
In 1984, Congress enacted the Drug Price Competition and
Patent Term Restoration ("Hatch-Waxman Act"), which amended
the Food, Drug, and Cosmetic Act in a successful bid to stimulate
generic competition and balance the needs of competing interests in
the pharmaceutical industry.8  The Hatch-Waxman Act was
Congress's response to the outcome of Roche Products, Inc. v. Bolar
Pharmaceutical Co.,9 in which the Federal Circuit held that the
generic firm infringed on a brand name sleeping pill when they began
63. Gitter, supra note 60, at 565.
64. Id. at 565-66.
65. Id. at 566.
66. Id. at 567.
67. Gitter, supra note 60, at 566.
68. Drug Price Competition and Patent Term Restoration Act of 1984, Pub. L. No.
98-417, 98 Stat 1585.
69. 733 F.2d 858 (Fed. Cir. 1984).
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experimenting with the original, patented product in order to satisfy
FDA testing requirements. The court found that the generic's use
was for "business reasons and not for amusement, to satisfy idle
curiosity, or for strictly philosophical inquiry."" Congress enacted the
Hatch-Waxman Act to reverse the holding in Roche Products by
specifically exempting the manufacture, use, or sale of a patented
invention from being liable for infringement when use was reasonably
related to generating data for regulatory approval (also known as the
"271(e)(1) exception").
Under Hatch-Waxman, generic drug applicants are not required
to conduct clinical testing of drugs that have already been proven to
be safe and effective. Instead, the applicant only needs to
demonstrate that the generic drug product is the equivalent of the
brand name drug, in effect, piggybacking off the brand name drug's
research and assurances of safety and effectiveness.73 This regulatory
scheme has "reduced prescription drug prices, increased access for
more Americans [to needed pharmaceuticals], and hastened the pace
of innovation." 74
There are two "shortcuts" offered by the Hatch-Waxman Act:
the abbreviated new drug application ("ANDA", also known as the
505(j) application), and the 505(b)(2) pathway." The ANDA
pathway allows drugs that are "identical or almost identical" to rely
on previously submitted NDA information of the brand name drug as
their reference material without necessitating clinical studies or other
proof of findings of safety and effectiveness. On the other hand, the
505(b)(2) pathway also allows reliance on the reference drug's
approved NDA data, but instead of requiring that the two molecules
be identical, the 505(b)(2) pathway permits the application of drugs
that are merely "similar" and not necessarily "identical" (e.g., a drug
with the "same composition but different proposed use than the
brand [name] drug").
70. Roche Products, Inc, 733 F.2d at 863.
71. Arie M. Michelsohn, 'Follow-On' Biologics, What Will It Take?, A.B.A. SCITECH
LAW., Fall 2008, at 4, 6.
72. Fed. Trade Comm'n, supra note 2.
73. Id.
74. Id. at 4.
75. Sahr, supra note 15, at 20-23.
76. Gitter, supra note 60, at 568-69.
77. Id. at 570.
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This Act also gives the first generic drug applicant to file a "first-
to-file" exclusivity for the first 180 days. This means that for six
months after the expiration of the brand name drug, the FDA will not
look at or approve of any other ANDAs." This creates incentive for
generic drug manufacturers to enter the market by being the first to
file. In this manner, the FDA effectively limits the market to two
players by refusing to allow any other ANDAs for that period of six
months.
C. The Approval Pathway for Pioneer Biologics and Follow-On
Biologics
As discussed earlier, a BLA is an application to obtain a license
to market a biologic. It must demonstrate that "the biological
product ... is safe, pure, and potent; and the facility in which the
biological product is manufactured, packed, or held meets standards
designed to assure that the biological product continues to be safe,
pure, and potent . . ."79
Twenty-five years after the enactment of the Hatch-Waxman
Act, there is still no equivalent approval process for biologics. In fact,
in order to obtain FDA approval, follow-on biologics must endure the
same testing and clinical trials as the original biologics in order to
determine their safety and efficacy."' Essentially, manufacturers of
new biologic products must apply for approval as if their product was
an entirely new drug rather than a generic equivalent of a preexisting,
pioneer biologic. The Hatch-Waxman Act specifically does not
address biologics for several reasons. When the Act was pending
before Congress in 1984, technology was ill-equipped to handle the
complexities of demonstrating equivalence and safety in follow-on
biologics. Legal analysis of the Act's legislative history reveals that in
order for the abbreviated pathway created by the Act to be
applicable, both the pioneer drug and the generic must be chemically
identical molecules."' The Hatch-Waxman Act emphasizes the
importance for determining that brand name and generic versions of
small-molecule chemical drugs are bioequivalent to one another.
Since it is extremely difficult to demonstrate bioequivalency between
two biologic products, the abbreviated approval process for chemical
drugs is inapplicable to biologics.
78. Gitter, supra note 60, at 573.
79. 42 U.S.C. § 262 (2009); see also 21 C.F.R. §§ 601.20-25 (2009).
80. Kaldre, supra note 3, at 17.
81. Gitter, supra note 60, at 575-76.
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IV. The European Union Has a Regulatory Scheme in Place for
an Abbreviated Approval Process for Biosimilars
A regulatory pathway for biosimilars has been in place in the
European Union ("E.U.") since 2003.82 E.U. legislation has declared
that the final decision to approve or reject a drug fell on the
European Commission (the European version of the FDA) and has
mandated comparative clinical trials, one year of testing, and risk-
management plans." European biosimilar manufacturers can claim
that their drug is "similar" to existing biologics by "comparing the
quality, safety, and efficacy of the new drug to the biologic," and
ensuring that the biosimilar and the original biologic have
comparable immunogenicity.
The E.U. is acutely aware of the dangers and disastrous
consequences of unpredictable immunogenicity after the tragic
incidents associated with Eprex@. With the dangers of
immunogenicity fresh in mind, the E.U. passed legislation for an
abbreviated regulatory pathway for biosimilars that compares the
quality, safety, and efficacy of the biosimilar applicant." Most
importantly, the applicant must show that the pioneer biologic and
the proposed biosimilar share comparable immunogenicity, a
requirement that often involves preclinical and clinical testing." Since
the E.U. passed this legislation, the European Commission has
approved two different generic human growth hormones, Omnitrope
and Valtropin." Other countries have since followed suit, with Japan
being the most recent country to implement a set of follow-on
biologic guidelines to accompany its previously established
accelerated drug approval system.'
V. The U.S. Currently has Several Bills Proposing Abbreviated
Approval Pathways for Follow-On Biologics
Generic biologics manufacturers and local governments are
insisting upon legislation to create an abbreviated approval process as
82. Kaldre, supra note 3, at 20.
83. Bryan A. Liang, Generic Safety Risks, THE AM. SPECTATOR (July 25, 2007),
http://spectator.org/archives/2007/07/25/generic-safety-risks.
84. Kaldre, supra note 3, at 21.
85. Kaldre, supra note 3, at 21.
86. Id.
87. Id.
88. See John A. Tessensohn & Shusaku Yamamoto, Japanese Biotech Patenting
Strategies in the Era of Follow-On Biologics, 28 BIOTECH L. REP. 483, 484, 490 (2009).
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well as a regulatory pathway for follow-on biologics." Congress has
responded by proposing several bills for abbreviated approval
pathways that are currently pending. Representative Henry Waxman
(D-CA) of Hatch-Waxman fame remarked at the Biosimilars 2007
Conference on September 24, 2007, that "[b]iotech drugs are the
future of medicine."" He is standing behind his statement by drafting
and supporting the bill entitled the "Promoting Innovation and
Access to Life-Saving Medicine Act" (H.R. 1427) (hereinafter
referred to as "Waxman's Bill") 9' Another bill standing before the
House is the "Pathway for Biosimilars Act" (H.R. 1548), which was
introduced by Representative Anna Eshoo (D-CA) (hereinafter
referred to as "Eshoo's Bill").9 Both Bills are discussed below.
A. Waxman's "Promoting Innovation and Access to Life-Saving
Medicine Act" (H.R. 1427)
After its success, the Hatch-Waxman Act of 1984 is a natural
reference for creating a regulatory pathway for follow-on biologics."
Rep. Waxman introduced the "Promoting Innovation and Access to
Life-Saving Medicine Act" on March 11, 2009, and this bill bears
many similarities to the Hatch-Waxman Act.94  For example,
Waxman's Bill follows the timeline of the Hatch-Waxman Act by
89. Kaldre, supra note 3, at 24.
90. Congressman Henry A. Waxman, Remarks at Biosimilars 2007 Conference (Sept.
24, 2007), available at http://www.biosimilarstoday.com/Waxman.pdf.
91. Promoting Innovation and Access to Life-Saving Medicine Act, H.R. 1427, 111th
Cong. (2009).
92. Pathway for Biosimilars Act, H.R. 1548, 111th Cong. (2009).
93. This is an arguable assertion, as most agree that the Hatch-Waxman Act has been
successful in increasing the entry of generic drugs into the market. Prices for chemical
drugs dropped as a result of the Act, and most states have encouraged health plans to
substitute or require generic drugs. The presence of generic drugs has saved consumers
billions of dollars, due to the fact that prices for drugs register a drop of 5% to 25% with
the entry of the first generic into a market, a drop of approximately 50% for the entrance
of a second generic, and by the time six or more generic drugs enter a market, the price
can fall to a quarter of its original, brand price. Michael A. Carrier, Unsettling Drug Patent
Settlements: A Framework for Presumptive Illegality, 108 MICH L. REV. 37, 50 (2009).
However, despite this, prices have recently been increasing. The rising trend may be
attributable to the use of reverse payments, in which brand drugs pay generics to abandon
patent challenges and delay their entrance into the market. Id. at 51.
94. A companion bill to Waxman's Bill is pending in the Senate, sponsored by
Senator Charles Schumer (D-NY), under the same title, was introduced on March 26,
2009. Promoting Innovation and Access to Life-Saving Medicine Act, S. 726, 111th Cong.
(2009). As the bill is identical to Waxman's Bill, this Paper will refer to Waxman's Bill
with the understanding that Schumer's bill is included in the same analysis.
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proposing similar exclusivity periods, and not requiring clinical trials.
Instead of conducting clinical trials, Waxman's Bill would allow
follow-on biologic applicants to rely upon the safety and efficacy data
of the reference biologic, much like the Hatch-Waxman Act allows
generic drugs to piggyback off brand name drugs' test data.96
Furthermore, Waxman's Bill mandates that follow-on biologic
applicants must demonstrate interchangeability with the brand name
biologic.
Waxman's Bill departs slightly from the Hatch-Waxman Act by
giving a 180 day period of first-to-file exclusivity after the first sale or
a full year after the approval of the first follow-on biologic found to
be interchangeable with the original biologic (the Hatch-Waxman Act
only gives a 180 exclusivity period.)" This exclusivity provision for
first-to-file applicants prevents the FDA from approving a similar
biologic product for sale to the public for a period of time after the
introduction of the first follow-on biologic.
A separate exclusivity period is also provided for the reference
biologic manufacturer. Waxman's Bill follows in the footsteps of the
Hatch-Waxman Act and provides pioneer biologic manufacturers
with a five year data exclusivity period. The FDA cannot approve
any generic versions of the biologic during this period.
B. Eshoo's 'Pathway for Biosimilars Act' (H.R. 1548)
Although both Eshoo's Bill and Waxman's Bill purportedly
share the same goal of finding a mechanism for the accelerated
approval of follow-on biologics, the two bills are substantially
different. On March 17, 2009, Reps. Anna Eshoo, Jay Inslee, and Joe
Barton introduced their version of a follow-on biologics bill, entitled
the "Pathway for Biosimilars Act" (H.R. 1548).'9 According to the
press release, the bill "sets forth a straightforward, scientifically based
95. Brian J. Del Buono, Moving Toward a Biosimilars Pathway: The Lines are Drawn
in Congress, 22 BIO PHARM INT'L., July 1, 2009, at 46, 48, available at http://
biopharminternational.findpharma.com/biopharm/GMPs/Validation/Moving-Toward-a-
Biosimilars- Pathway-The- Lines-are-/ArticleStandard/Article/detail/608685.
96. Id.
97. Id.
98. Promoting Innovation and Access to Life-Saving Medicine Act, H.R. 1427, 111th
Cong. § 3(a)(2)(k)(11)(A) (2009).
99. Congresswoman Anna Eshoo, Reps. Eshoo, Inslee, and Barton Introduce Pathway
for Biosimilars Act, Website of Congresswoman Anna G. Eshoo (D - CA) (March 17,
2009, 12:19 PM), available at http://eshoo.house.gov/index.php?option=comcontent
&task=view&id=581&Itemid=79 (quoting Rep. Eshoo's statement describing the new
bill).
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process for expedited approval of new biologics based on innovative
products already on the market."""' Eshoo's Bill leans heavily toward
incentivizing brand name developers to continue developing
innovative drugs by providing lengthy exclusivity periods. While
Waxman's Bill gives original biologic manufacturers a five-year
period exclusivity, Eshoo's Bill mandates at least 12 years of data
exclusivity (extendable up to 14.5 years) for pioneer biologics."'o On
the other hand, Eshoo's Bill also allows for a longer period of
exclusivity for generic biologics, awarding up to two years of market
exclusivity to the first follow-on biologic found to be interchangeable
with the original product.
Eshoo's Bill further requires that a generic biologic applicant
establish that the proposed product is "biosimilar" to the reference
biologic. Each follow-on biologic applicant must complete a period
of clinical trials comparing the immunogenicity of the applicant's
product with the original biologic. Analytical studies must show that
the proposed biological product is highly similar in toxicity, safety,
purity, and potency.
C. Exclusivity Periods
The provisions in Waxman's and Eshoo's Bills that generate the
most attention in interested parties are the exclusivity periods. The
bills provide for two exclusivity periods: (1) for the first-to-file follow
applicants, preventing the FDA from approving similar follow-on
biologic applicants for a specified period of time after the
introduction of the first follow-on biologic applicant, and (2) for
pioneer biologics, allowing for a period of data exclusivity that
prevents the FDA from approving any follow-on versions of the
biologic until the period has expired. The exclusivity period for first-
to-file applicants acts as an incentive for generic biologic developers
by creating a two-entity market. This reduces competition and allows
for a higher profit margin. The exclusivity period for pioneer
biologics promotes continued innovation and acts as a mitigation
factor, providing the original biologic with the time lost due to the
wait for FDA approval. The exact length of each exclusivity period
has been analyzed and debated extensively. Extensive research has
been conducted to determine the optimal length of time for
100. Eshoo, supra note 99.
101. Pathway for Biosimilars Act, H.R. 1548, 111th Cong. § 101(a)(2)(k)(7)(A),
(a)(2)(k)(8)(A)(ii) (2009).
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extensions and various other economic aspects of biotechnology.1 2
Earlier this year, the White House voiced an opinion on this matter
by sending a letter to Rep. Waxman recommending a seven year data
exclusivity period for pioneer biologics.13
VI. Proposal
The generic biologic approval framework that this paper
proposes aims to balance the safety concerns of biologic drugs against
the need for an accelerated approval process. It is imperative that
any regulatory pathway balance the needs of the pioneer biologic
developers, follow-on biologic manufacturers, and the American
public. The current bills pending approval in Congress are heading in
the right direction, but still need refinement.
A. Inevitability: It is Only a Matter of Time Before an Abbreviated
Approval Pathway is Approved
The purpose of creating an abbreviated approval pathway for
follow-on biologics is to stimulate generic competition while
simultaneously providing incentives for innovation. Brand name
companies and other industry opponents of developing this pathway
argue that the reason biologic drugs were not originally included in
the Hatch-Waxman framework was because of the difficulty of
characterizing biologics to ensure equivalency.104 First, the opponents
of creating an abbreviated approval pathway must recognize that the
creation of such a regulatory pathway is just a matter of time. The
rising costs of biologics has already put a strain on the U.S. healthcare
system, creating a pressing need for cheaper biologics, especially in
light of the recent economic environment, and the best solution for
the cost problem is promoting the availability of generic biologics. In
order to offset the costs that inherently make biologics expensive to
develop and manufacture and to incentivize generic drug
manufacturers to enter the follow-on biologics arena, an abbreviated
approval system is the best approach. Second, the inadequacy of
scientific knowledge, which opponents often cite, may have been a
102. See Henry G. Grabowski, Patents and New Product Development in the
Pharmaceutical and Biotechnology Industries, 2003 SCIENCE & CENTS: EXPLORING THE
ECONOMICS OF BIOTECHNOLOGY 87, 93 available at http://www.dallasfed.org/
research/pubs/science/science.pdf
103. White House: 7 Years Enough to Shield Biotech Drugs, REUTERS (June 25 2009),
http://www.reuters.com/article/idUSTRE5506ZZ20090625
104. Gitter, supra note 60, at 590.
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legitimate concern in 1984 when the Hatch-Waxman Act was first
approved by Congress, but scientific progress over the past twenty-six
years has advanced technology sufficiently that current techniques
permit follow-on biologic product manufacturers to accurately assess
their products for comparability with brand name products." While
there is no single method that is capable of establishing the
comparability of biologics on its own, there are now many analytical
technologies that can be used to confirm protein configuration."o
Such technologies include orthogonal protein purification,
hyphenated mass spectrometry, isoelectric focalization, and SDS-
PAGE.1
B. Immunogenicity Mitigated as a Concern by Imposing a Required
One-Year Clinical Study Period
The biggest concern regarding a regulatory pathway for follow-
on biologics is, of course, safety-specifically, immunogenicity. The
often cited example of the dangers of follow-on biologics is the
immunogenicity caused by Eprex. Recent research has found,
however, that the increased incidence of pure red cell aplasia with
Eprex may be due to its manufacture using uncoated rubber stopper
syringes (i.e., immunogenicity caused by the packaging of the biologic
rather than the biologic itself)." According to a group's research
results, "[a] technical investigation identified organic compounds
leached from uncoated rubber stoppers in prefilled syringes
containing polysorbate 80 as the most probable cause of the increased
immunogenicity."' As such, this example illustrates that the
purported dangers of biologics does not necessarily exist only in
biologics, but may be a possibility in any manufactured drug.
Nevertheless, it is evident that some clinical testing should be
required to ensure public safety. Waxman's Bill removes the clinical
trial requirement completely from the table, allowing the follow-on
biologic to completely rely on the pioneer biologic's clinical research
105. See Henry Grabowski et al., The Market for Follow-On Biologics: How Will It
Evolve?, 25 HEALTH AFF. 1291, 1293-94 (2006).
106. Analytics and Follow-On Biologics: So Close and Yet So Far, PHARMA
MANUFACTURING.COM, http://www.pharmamanufacturing.com/articles/2007/065.html
(last visited December 18, 2009).
107. See Analytics, supra note 106.
108. Katia Boven et al., The Increased Incidence of Pure Red Cell Aplasia with an
Eprex Formulation in Uncoated Rubber Stopper Syringes, 67 Kidney International 2346
(2005).
109. Id.
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data. Prudence requires that a period of clinical testing still be
performed on follow-on biologics. Although advances in technology
have made it so that a "follow-on protein product is likely to meet the
requisite standards for identity, potency, purity, quality, and safety,"'o
biologics are, as mentioned above, still extremely complex molecules.
Therefore, I propose that the abbreviated approval pathway
require a one year period of clinical trials. Europe currently
mandates a one year clinical trial period to demonstrate
comparability between biosimilars and pioneer biologics. The E.U. is
wary of approval pathways for follow-on biologics because of issues
identified with the introduction of Eprex, and yet they assert that a
one year clinical trial period is sufficient. I believe that the U.S.
should follow suit and require a one year period of clinical trials in
order to establish follow-on biologics' safety.
Waxman's Bill completely discards the requirement for clinical
trials altogether."' This is unwise in light of the complex nature of
biologics and the fact that creating and guaranteeing follow-on
biologics to be identical in every way to their reference biologic is
nearly impossible. Despite the fact that technology now allows for
better characterization of biologics, the possibility of immunogenicity
is still present. Eshoo's Bill requires clinical trials to determine the
immunogenicity of proposed follow-on biologics, but the language of
the bill does not give a minimum requirement for clinical trials. This
gives too much discretion to the FDA, and although the FDA has its
own set of regulations to ensure safety, a minimum requirement for a
period of clinical testing will only aid in ensuring the safety of follow-
on biologics.
Thus, a one year clinical trial period would help protect
consumers from safety concerns stemming from biological products,
such as varying immunogenicity. As discussed above, we should look
comparatively at foreign systems when determining what period of
time would be effective and efficient. The E.U. is an ideal model for
the United States because drug patents in Europe tend to expire
earlier than those in the U.S., and European manufacturers have
already begun to seek approval for biosimilars."2 Experience with
creating an abbreviated approval pathway for biosimilars in Europe
110. Gitter, supra note 60, at 599.
111. Promoting Innovation and Access to Life-Saving Medicine Act, H.R. 1427, 111th
Cong. (2009).
112. Gottlieb, supra note 17, at S7.
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can therefore be a model from which the United States can develop
its regulatory system.
C. Language for Follow-On Biologics Must Ensure that They are
'Substitutable' Rather Than Merely 'Biosimilar'
Any approval pathway for follow-on biologics, regardless of
whether it is abbreviated or not, must require that the applying
biologic be held to a higher, "substitutable" standard. This would
require the applicant to demonstrate that the incoming drug
demonstrates a "sameness" with respect to its reference biologic. The
interchangeability and therapeutic equivalence of biologics cannot be
based on the same standards and criteria used for comparing small-
molecule chemical drugs. While it is widely accepted that two drugs
consisting of the same chemical structure are sufficiently equal
counterparts, the complexity of protein synthesis makes it improbable
that two products made with differing processes can be considered
equal. Therefore it is imperative that a new standard for
comparability between biological products be established. The FDA
has found that large protein products with similar compositions may
behave markedly different in different individuals and could result in
cases of immunogenicity or adverse side effects."
The language of any proposed legislation is critical in ensuring
that future follow-on biologics are as safe, effective, and reliable as
the original biologic they are based upon. Inadequate definitions in
the language of the bill may also lead to confidence issues among
physicians. If follow-on biologics are merely labeled as "highly
similar," doctors may be more reluctant to prescribe generic versions
of the biologic, which would defeat the cost-saving goals of follow-on
biologics. By specifically defining "substitutable" to mean a higher
standard to which follow-on biologics must satisfy, both doctors and
patients can be assured a safer product. However, to have a
"substitutable" standard would require a clear definition of what is
"substitutable" versus what is merely "highly similar." This section
examines the proposed bills' definitions and requirements for
comparability between follow-on and pioneer biologics and then
introduces a different standard for comparability that emphasizes
follow-on biologics' substitutability with the original biological
product.
113. Gottlieb, supra note 17, at S5.
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Waxman's Bill allows an applicant to rely on the data from the
reference biologic in applying for approval as long as the applicant
can show "that the biological product and the reference product
contain highly similar molecular structural features."ll 4 The proposed
biologic must be "biosimilar" meaning that it is interchangeable with
the reference biologic."5 According to the bill, a product is
"biosimilar" if there are "no clinically meaningful differences between
the biological product and the reference product ... in terms of the
safety, purity, and potency.""' If a patient's treatment demands that a
biologic be administered more than once, the proposed follow-on
biologic must allow a patient to be able switch between the brand
name and generic versions of the biologic "without an expected
increase in the risk of adverse effects, including a clinically significant
change in immunogenicity, or diminished effectiveness, compared to
the expected risks from continuing to use the reference product
without such switching.""' Once more, the wording of "clinically
meaningful differences" is unclear as it currently stands in the Bill.
The ambiguity of the definition would allow too much room for
variability between follow-on and original biologics.
On the other hand, Eshoo's Bill is less lenient than Waxman's
Bill with regard to proof of similarity. It requires that the follow-on
biologic applicant must show that "the biological product ... is
biosimilar to the reference product and any biological product
licensed ... that has been determined to be interchangeable with the
reference product; and can be expected to produce the same clinical
result as the reference product . .." and can be used interchangeably
with the reference product in situations where the biologic product
must be administered more than once to a patient."
Interchangeability is therefore based on whether a proposed product
is "biosimilar" to the original product at the Secretary of Health and
Human Services' discretion.
Both Waxman's and Eshoo's Bills focus on using the vaguely
defined term "interchangeability" of biologics instead of looking
114. Promoting Innovation and Access to Life-Saving Medicine Act, H.R. 1427, 111th
Cong. § 3(a)(2)(k)(5) (2009).
115. Id. at § 3(a)(2)(k)(2).
116. Id. at § 3(a)(2)(k)(1) (emphasis added).
117. Promoting Innovation and Access to Life-Saving Medicine Act, H.R. 1427, 111th
Cong. § 3(a)(2)(k)(2)(B) (2009).
118. Pathway for Biosimilars Act, H.R. 1548, 111th Cong. § 101(a)(2)(k)(4)(A)(i)
(2009).
119. Id.
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toward determining their sameness. The Bills would permit
molecular differences between proposed follow-on biologics and
pioneer biologics, allowing for increased safety risks to patients. The
definition of "substitutable" should be one that requires a proposed
follow-on biologic and a pioneer biologic to be the same with regard
to their immunogenicity, safety, quality, and efficacy.
Ultimately an abbreviated approval pathway should provide
strict, statutory rules as to the length of the clinical trial period, the
exclusivity periods, and the various specifics that ensure a safe but
cost effective product.
D. The FDA Should Set Up Guidelines for Well Characterized Follow-
On Biologics
In addition to the statutory guidelines, the FDA should set up
guidelines for approving follow-on versions of well-known biologics
such as insulin. Insulin, as well as improvements made on it, has been
around for a long time, and its patent expired years ago.12 ) The
number of diabetics is growing in this country, and healthcare
providers and government officials are eager to find cheaper
alternatives to insulin.121 The same applies to human growth
hormones.12 Because insulin and growth hormones were approved
originally as regular drugs, the FDA now "has the legal authority to
approve generic versions."l' Approval by the FDA would be faster
and would be able to address health and cost concerns almost
immediately, instead of waiting for the undeterminable for Congress
to implement an abbreviated approval pathway. In 2001, the FDA
began developing regulatory advice for companies seeking to make
follow-on biologic versions of insulin and human growth hormone,
but has recently delayed final guidelines.124
In fact, the FDA has approved a generic biologic drug in the
past: Omnitrope, a recombinant growth hormone used for treating
"pediatric patients who suffer growth failure and adults with growth
120. Insulin's patent was issued to the University of Toronto, and the patent has since
expired. Robert D. Simoni et al., The Discovery of Insulin: The Work of Frederick Banting
and Charles Best, 277 J. Biological Chemistry 31, 31 (2002).
121. States Petition US FDA on Generic Insulin, Hormone, REUTERS, 1 (Aug. 3,2006),
(available in LexisNexis- under "News & Business" search in "Reuters News" for article
title).
122. Id.
123. Id. at 2.
124. Id.
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hormone deficiency." 125 Omnitrope was originally filed as an NDA,
and for a period of time the FDA kept trying to defer making a
decision on Omnitrope When it was ultimately forced to make a
decision, the FDA approved Omnitrope under the 505(b)(2) pathway
mentioned supra.126 It based its approval of Omnitrope on a finding
that Omnitrope was "sufficiently similar" to Pfizer's Genotropin.12 1
The FDA was able to do this because Omnitrope is not very complex,
it has a "long and well documented history of clinical use," and there
was already existing information about its pharmacokinetic
properties, and this information allowed the FDA to establish
similarity to Genotropin without relying on "chemistry,
manufacturing, and control ... data.,128
The FDA cautioned against expecting that all follow-on versions
of a biologic following this path would be approved, and it is true that
not all generic versions of biologics necessarily should go through the
505(b)(2) pathway for approval. But where a biologic such as insulin
is well known and fully characterized, safety is no longer in
contention and rising costs greatly outweigh the safety concerns. The
best course of action would be for the FDA to have guidelines for
speeding up the approval of these follow-on biologics.
VII.Conclusion
Biologics are rapidly growing in importance in the medical world.
The ability of biopharmaceutical drugs to replace natural proteins
produced by the body make them invaluable as therapy regimens to
target major disease including cancer, infectious agents, and a variety
of other health conditions However, the immense cost of treatment
with biologics can reach hundreds of thousands of dollars a year, an
expense that puts treatment out of reach for many patients who could
potentially benefit. The costs of biologics are also impacting the
current healthcare crisis, and therefore the arrival of an abbreviated
approval process for follow-on biologics is inevitable and must be
both examined and discussed.
Consideration of the current drug approval system (the Hatch-
Waxman Act) and the available options for a regulatory pathway for
generic biologics (Waxman's and Eshoo's Bills) reveals that the bills
125. Gitter, supra note 60, at 577-78.
126. Id. See also Sahr, supra note 15, at 20-23.
127. Gitter, supra note 60, at 578.
128. Gitter, supra note 60, at 578.
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currently pending before Congress still need revision. Specifically,
the bills should include a statutory requirement for a one year clinical
trial period to examine the immunogenicity and ensure the safety of
follow-on biologics. Also, follow-on biologics should be held to a
higher, "substitutable" standard when being compared with the
original brand biologics, requiring that the follow-on biologic be
sufficiently the "same" as the original, pioneer biologic. Additionally,
while the bills before Congress await approval, the FDA should set
up guidelines to allow for the approval of follow-on versions of well
known biologics such as insulin and human growth hormone whose
patents have already passed expiration. Considering the importance
of biologics as a growing field of medicine that treats many medical
ailments, Congress should ensure an abbreviated approval process for
follow-on biologics. An abbreviated process with a mandatory one
year clinical testing period that requires a follow-on biologic to be the
same as its reference biologic would be the best option to address the
issues currently facing biologics.
